South Carolina House Bill H4382

South Carolina 2025-2026 Regular Session

• Introduced: 4/23/25
• Refer: 4/23/25
• Engrossed: 4/30/26
• Refer: 4/30/26
• Enrolled: 5/14/26
• Passed: 5/19/26

Caption

Nonprescription Ephedrine Products

Impact

The legislation imposes additional responsibilities on retailers selling nonprescription products containing ephedrine and pseudoephedrine. Starting October 1, 2026, manufacturers will also be required to pay monthly fees related to the data collection system, which is overseen by the National Association of Drug Diversion Investigators. This inclusion aims to create a sustainable financial model for the continued monitoring and enforcement of regulations concerning the sale of these substances, thereby integrating state oversight directly into the manufacturing process.

Summary

House Bill 4382 is aimed at amending the South Carolina Code of Laws by specifically modifying Section 44-53-398, which pertains to the sale of products containing ephedrine or pseudoephedrine. The bill introduces new requirements such as the mandatory collection of data by retailers when selling these products. Retailers must now obtain government-issued photo identification from purchasers, requiring them to sign an electronic log documenting the transaction details. This change is expected to enhance oversight and track the sales of these potentially abused products more effectively.

Sentiment

The sentiment surrounding HB 4382 appears to be generally positive among lawmakers, as evidenced by its passage with a unanimous vote of 107-0. Supporters argue that this legislative measure is a proactive step in combating drug misuse while ensuring that legitimate consumers can still access necessary medications. However, there is underlying concern from some community members and retailers about the added compliance costs and the logistics of maintaining detailed electronic logs, as these might burden smaller retailers disproportionately.

Contention

Notably, there are points of contention regarding the penalties established in the bill for violations. The penalties for retailers or manufacturers who fail to comply with these new regulations include significant fines, which may reach up to ten thousand dollars for repeated offenses. Critics may argue that such steep penalties could deter retailers from stocking these products altogether, potentially leading to access issues for individuals needing legitimate treatment. The implementation mechanics for the data collection system also raise questions about privacy and the administrative burden on businesses.